European Pharmaceutical Review

The leading FREE journal for up-to-the-minute information and news on all aspects of drug analysis, formulation, delivery, manufacturing and regulation.

[European Pharmaceutical Review @PharmaReview]

According to analysis by @moderna_tx, 20 percent of participants in UK industry-sponsored clinical research were enrolled in a Moderna trial in 2023/2024. https://t.co/uiuEAZBA95

[European Pharmaceutical Review @PharmaReview]

“Excitingly, advances in gene editing are happening very rapidly... it seems likely that cheaper, safer and more effective forms of gene editing will emerge for sickle cell disease over the coming years,” commented Professor Rees of King’s College London.
https://t.co/5qSvafjeFw

[European Pharmaceutical Review @PharmaReview]

"This year’s figures demonstrate that biotech is a vibrant growth sector of the UK economy with an exceptional ability to attract global investment," says @BIA_UK's CEO. https://t.co/1KzWzKKIaE

[European Pharmaceutical Review @PharmaReview]

@US_FDA 's approval offers patients opportunity to "experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral antidepressants,” explained Global Therapeutic Area Head, Neuroscience, @JNJInnovation https://t.co/l67CRnH0vr

[European Pharmaceutical Review @PharmaReview]

"With nearly two-thirds of all major #pharma company revenues set to come from dealmaking in the next five years, deals will remain at the centre of #lifesciences strategy," says @EYnews Global Life Sciences Deals Leader. https://t.co/MJH1QgKlQ7

[European Pharmaceutical Review @PharmaReview]

Oncology continues to be the dominant area in early-phase ATMP clinical trials for investigational therapies, the report data shows. #pharma #clinicaltrials https://t.co/j3JvqMgoIz

[European Pharmaceutical Review @PharmaReview]

The new recommendations will support health technology assessment (HTA) and aid technology developers to provide data for evidence submissions. https://t.co/JnBhNjZGEr

[European Pharmaceutical Review @PharmaReview]

The acquisition will include rights to a TKI molecule, which according to @GSK's CSO, has potential to help close a major gap in the current standard of care of gastrointestinal stromal tumours.
https://t.co/zSBf6rA50O

[European Pharmaceutical Review @PharmaReview]

Gene editing technologies are expected to innovate #pharma personalised medicine in 2025, says @ClarivateHealth 's latest Drugs to Watch report. #drugdevelopment
https://t.co/yxIwfy8eXs

[European Pharmaceutical Review @PharmaReview]

As part of the agreement, @bmsnews is responsible for development and commercialisation of the novel antibodies and related products. #biologics #EPRtalks https://t.co/9gGR1FxpAS

[European Pharmaceutical Review @PharmaReview]

@novonordisk's production facility will utilise advanced technology and innovative equipment to meet growing global demand #pharmaceuticalmanufacturing #EPRtalks https://t.co/rGw2OVTEc2

[European Pharmaceutical Review @PharmaReview]

"Approval by the [European Commission] is significant because Elahere is the first new medication approved specifically for platinum-resistant ovarian cancer since 2014". #pharma #EPRTalks https://t.co/bd6TflhE8l

[European Pharmaceutical Review @PharmaReview]

"These reforms protect the safe development of pioneering new treatments," Dr June Raine, @MHRAgovuk Chief Executive stated. #EPRTalks
https://t.co/BAjBOss9Hy

[European Pharmaceutical Review @PharmaReview]

“By combining our expertise in #clinicaltrials and #lifesciences with world-class researchers, we can accelerate the development of groundbreaking treatments that will benefit patients across [the UK and Switzerland]” says UK Health Minister. #EPRTalks https://t.co/U0ZEuMjENP

[European Pharmaceutical Review @PharmaReview]

AD | Making spirits bright!

Save 25% and enjoy free gummi bears with our most popular nucleic purification kits.

Whether you’re looking for #DNA, #RNA, or #plasmidpurification, clean-up for #NGS, gels, or PCR, we’ve got the perfect kit.

https://t.co/64uaA5CjBu

[European Pharmaceutical Review @PharmaReview]

The new appointments by @Amgen and @pfizer will drive development of new medicines across numerous therapeutic areas such as rare disease and cancer. https://t.co/v0W6ghJjxE #EPRTalks

[European Pharmaceutical Review @PharmaReview]

Investment in @sanofi's Lyon Gerland site will aid internal bioproduction of a type 1 #diabetes drug, enabling market availability in 2027. https://t.co/3Eph5Iv9Md #pharmaceuticalmanfacturing #EPRTalks

[European Pharmaceutical Review @PharmaReview]

As part of the acquisition, @BioNTech_Group will gain rights to a state-of-the-art biologics manufacturing facility. https://t.co/GONCfRIr5E #biologics #EPRTalks

[European Pharmaceutical Review @PharmaReview]

@AstraZeneca's recent US investment is part of the company's plan to secure $80 billion in Total Revenue by the end of 2030. #Pharmaceutical #EPRTalks https://t.co/T9F56TTkhM

[European Pharmaceutical Review @PharmaReview]

🚨 Last Chance! 🚨

Join us this week for a webinar with Vivien Knospe from FUJIFILM WAKO Chemicals on the Monocyte Activation Test (MAT)!

📅 Register now: https://t.co/b2zNcYSe6A

#mat #monocyteactivationtest #webinar